-
Je něco špatně v tomto záznamu ?
HPLC/UV/MS method application for the separation of obeticholic acid and its related compounds in development process and quality control
M. Douša, M. Slavíková, T. Kubelka, J. Černý, P. Gibala, J. Zezula,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, validační studie
- MeSH
- chemická frakcionace přístrojové vybavení metody MeSH
- farmaceutická chemie metody MeSH
- hmotnostní spektrometrie s elektrosprejovou ionizací přístrojové vybavení metody MeSH
- kontaminace léku prevence a kontrola MeSH
- kyselina chenodeoxycholová analogy a deriváty analýza chemie MeSH
- limita detekce MeSH
- příprava léků přístrojové vybavení metody MeSH
- reprodukovatelnost výsledků MeSH
- řízení kvality * MeSH
- senzitivita a specificita MeSH
- spektrofotometrie ultrafialová přístrojové vybavení metody MeSH
- vysokoúčinná kapalinová chromatografie přístrojové vybavení metody MeSH
- Publikační typ
- časopisecké články MeSH
- validační studie MeSH
An HPLC method with UV and electrospray ionization - mass spectrometry (ESI-MS) detection was developed for the separation and determination of obeticholic acid (OBE) and its related compounds in development process and quality control. OBE and its related compounds were classified into three major group based on the mass spectra profiles: (A) those containing a hydroxyl group at position 3 and 7, (B) those containing a hydroxyl group and/or carbonyl group at position 3, hydrogen, ethyl or ethylidene group at position 6 and a hydroxyl group and/or carbonyl group at position 7, and (C) those containing carbonyl groups at position 3 and 7. ESI-MS ionization of OBE and its related compounds often produced intense adduct ions [M+H+98]+ and/or [M+H+196]+ that were identified as the adduct ions of phosphoric acid ([M+H+H3PO4]+ and [M+H+2H3PO4]+) originating from the mobile phase. The separation on HPLC system was accomplished using stationary phase based on XSelect CSH C18 (3.0×150mm×2.5μm) and a linear gradient elution using acetonitrile and 0.05% of o-phosphoric acid. The condition of chromatographic system was set as follows: flow rate 0.7mL/min, temperature 45°C and UV detection at 192nm. The separation of the 19 compounds was finished in less than 18min (including equilibration time). The HPLC/UV method was partially validated according to International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines in terms of repeatability, selectivity, linearity and limit of quantification and detection.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18033577
- 003
- CZ-PrNML
- 005
- 20181009110307.0
- 007
- ta
- 008
- 181008s2018 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jpba.2017.11.018 $2 doi
- 035 __
- $a (PubMed)29126083
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Douša, Michal $u Zentiva, k.s. Praha, A Sanofi Company, U Kabelovny 130, 102 37 Praha 10, Czech Republic. Electronic address: michal.dousa@seznam.cz.
- 245 10
- $a HPLC/UV/MS method application for the separation of obeticholic acid and its related compounds in development process and quality control / $c M. Douša, M. Slavíková, T. Kubelka, J. Černý, P. Gibala, J. Zezula,
- 520 9_
- $a An HPLC method with UV and electrospray ionization - mass spectrometry (ESI-MS) detection was developed for the separation and determination of obeticholic acid (OBE) and its related compounds in development process and quality control. OBE and its related compounds were classified into three major group based on the mass spectra profiles: (A) those containing a hydroxyl group at position 3 and 7, (B) those containing a hydroxyl group and/or carbonyl group at position 3, hydrogen, ethyl or ethylidene group at position 6 and a hydroxyl group and/or carbonyl group at position 7, and (C) those containing carbonyl groups at position 3 and 7. ESI-MS ionization of OBE and its related compounds often produced intense adduct ions [M+H+98]+ and/or [M+H+196]+ that were identified as the adduct ions of phosphoric acid ([M+H+H3PO4]+ and [M+H+2H3PO4]+) originating from the mobile phase. The separation on HPLC system was accomplished using stationary phase based on XSelect CSH C18 (3.0×150mm×2.5μm) and a linear gradient elution using acetonitrile and 0.05% of o-phosphoric acid. The condition of chromatographic system was set as follows: flow rate 0.7mL/min, temperature 45°C and UV detection at 192nm. The separation of the 19 compounds was finished in less than 18min (including equilibration time). The HPLC/UV method was partially validated according to International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines in terms of repeatability, selectivity, linearity and limit of quantification and detection.
- 650 _2
- $a chemická frakcionace $x přístrojové vybavení $x metody $7 D005591
- 650 _2
- $a farmaceutická chemie $x metody $7 D002626
- 650 _2
- $a kyselina chenodeoxycholová $x analogy a deriváty $x analýza $x chemie $7 D002635
- 650 _2
- $a vysokoúčinná kapalinová chromatografie $x přístrojové vybavení $x metody $7 D002851
- 650 _2
- $a příprava léků $x přístrojové vybavení $x metody $7 D004339
- 650 _2
- $a kontaminace léku $x prevence a kontrola $7 D004340
- 650 _2
- $a limita detekce $7 D057230
- 650 12
- $a řízení kvality $7 D011786
- 650 _2
- $a reprodukovatelnost výsledků $7 D015203
- 650 _2
- $a senzitivita a specificita $7 D012680
- 650 _2
- $a hmotnostní spektrometrie s elektrosprejovou ionizací $x přístrojové vybavení $x metody $7 D021241
- 650 _2
- $a spektrofotometrie ultrafialová $x přístrojové vybavení $x metody $7 D013056
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a validační studie $7 D023361
- 700 1_
- $a Slavíková, Markéta $u Zentiva, k.s. Praha, A Sanofi Company, U Kabelovny 130, 102 37 Praha 10, Czech Republic.
- 700 1_
- $a Kubelka, Tomáš $u Zentiva, k.s. Praha, A Sanofi Company, U Kabelovny 130, 102 37 Praha 10, Czech Republic.
- 700 1_
- $a Černý, Josef $u Zentiva, k.s. Praha, A Sanofi Company, U Kabelovny 130, 102 37 Praha 10, Czech Republic.
- 700 1_
- $a Gibala, Petr $u Zentiva, k.s. Praha, A Sanofi Company, U Kabelovny 130, 102 37 Praha 10, Czech Republic.
- 700 1_
- $a Zezula, Josef $u Zentiva, k.s. Praha, A Sanofi Company, U Kabelovny 130, 102 37 Praha 10, Czech Republic.
- 773 0_
- $w MED00002894 $t Journal of pharmaceutical and biomedical analysis $x 1873-264X $g Roč. 149, č. - (2018), s. 214-224
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29126083 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20181008 $b ABA008
- 991 __
- $a 20181009110755 $b ABA008
- 999 __
- $a ok $b bmc $g 1340211 $s 1030571
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 149 $c - $d 214-224 $e 20171104 $i 1873-264X $m Journal of pharmaceutical and biomedical analysis $n J Pharm Biomed Anal $x MED00002894
- LZP __
- $a Pubmed-20181008